Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Research and development innovations poised to cure more ills

By David Ho in Hong Kong | China Daily | Updated: 2019-04-10 09:28
Share
Share - WeChat

In mid-December, Shanghai Junshi Biosciences raised $394 million after pricing a Hong Kong initial public offering at the bottom of a marketed range.

At the same time, the Shanghai company's new drug Toripalimab was conditionally approved for the treatment of melanoma, becoming the first made-in-China immuno-therapy treatment for cancer to be approved by the National Medical Products Administration.

For Lewis Ho, a partner in the life sciences practice at law firm Loeb & Loeb, the start of the nation's healthcare research and development can be traced to 2006.

At the time, Ho was working with GlaxoSmithKline in Shanghai, and in 2007, GSK was one of the first multinationals to open a research and development center in China, focusing on neurodegenerative diseases.

By 2012, a report by management consultants McKinsey & Company said that 13 of the top 20 global drugmakers had set up R&D centers in China since 2006.

Ho said: "This sparked a new wave of research in the country. Government, academic and commercial organizations needed researchers. Chinese scientists were coming back from abroad and discovering a whole new world. Many of them went on to set up their own companies."

Funding remained a problem, particularly since the Hong Kong Stock Exchange, a big source of capital-raising for many companies in Asia, did not allow listings from companies that had not yet made a profit. But that rule changed last year.

"Many of these companies are maturing. It's a great time for the Hong Kong Stock Exchange to catch the next wave," Ho said.

Hong Kong Exchanges and Clearing posted new rules in April last year, which included allowing listings by biotech companies that had yet to make any money.

As of Dec 24, five such companies had listed on the Hong Kong bourse under the new rules. Another eight are in line for listing consideration.

HKEX has also formed a Biotech Advisory Panel - comprising industry experts - to advise and assist in the review of listing applications from biotech companies applying under the new regimen.

Ho said the first batch of companies that "dipped their toes in the HKEX pond" are safe bets. All of them have products in phase 3 clinical trials.

He expects that as the market matures and investors become more familiar with the biotech scene, more companies with early-stage products will start listing.

Ho said biotech companies on the Chinese mainland are choosing to list in Hong Kong because of the market size and the speed at which listings are approved.

"With the Shanghai Stock Exchange, it is harder to estimate when a listing will be approved, due to regulatory uncertainty, longer processing time and priority treatment for different industries. In Hong Kong, you get a sense of the IPO in about six months to a year," he said.

"More mature markets, like the Nasdaq Stock Exchange (in the United States) are too big for these emerging companies," he added.

"The Chinese government wants to push its biotech industries to succeed. Twelve years ago, there were no Chinese companies in the top 100 - now, there are about three on that list, with interesting products to launch," Ho said.

The country has also been revamping its regulatory system. In September, the China Food and Drug Administration was restructured and renamed the National Medical Products Administration.

The NMPA has introduced faster approvals for new drugs and added a priority list of 48 drugs for rare diseases. Those chosen were approved by the authorities in the United States, the European Union and Japan, but have not been registered in China for the past decade.

"The registration and approval process is happening a lot faster than before. Some companies are finding that they have been given approval two years before they expect it. So now there is a mad scramble to recruit sales representatives and for sales preparation," Ho said.

The inclusion of drugs in reimbursement programs is an area that needs to be improved.

The national reimbursement drug list determines the framework for the drugs covered by insurance at national level. It consists of two categories: List A drugs that are clinically necessary and sufficiently affordable to be fully reimbursed, and List B drugs that are newer, more expensive and require patients to pay 10 to 30 percent of the price.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 免费人妻av无码专区| 国产高潮国产高潮久久久| 亚洲av无码之日韩精品| 精品久久久久久国产| 国产成人一区二区三区免费视频| 9久热这里只有精品免费| 日日碰狠狠添天天爽爽爽| 亚洲国产日韩在线| 福利一区二区三区视频在线观看 | 中国女人一级毛片| 果冻传媒李琼母亲| 你懂得视频在线观看| 色香蕉在线观看| 国产男女猛视频在线观看| 99在线视频精品| 成人午夜精品久久久久久久小说| 久久综合久综合久久鬼色| 欧美爽爽爽爽爽爽视频| 公交车上被弄进走不动| 超级香蕉97在线观看视频| 国产精品久久久久久搜索| 99热这里只有精品免费播放| 成人综合伊人五月婷久久| 久久精品桃花综合| 欧美成人免费在线| 伊人久久精品一区二区三区| 绿巨人在线视频免费观看完整版| 国产女人18毛片水真多18精品 | 好吊妞视频这里有精品| 丰满岳乱妇一区二区三区| 最新国产精品亚洲| 亚洲欧洲日产国产最新| 男人桶爽女人30分钟视频动态图| 四虎影视免费永久在线观看| 骚视频在线观看| 国产精品igao视频网网址| 91福利免费视频| 天天av天天翘天天综合网| 一千零一夜电影无删减版在线看| 教师mm的s肉全文阅读| 久久国产精品免费一区二区三区 |